[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365801-105":59,"doc-detail-365801-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","applications-and-challenges-of-patient-derived-organoids-in-hepatobiliary-and-pancreatic-cancers","Applications and challenges of patient-derived organoids in hepatobiliary and pancreatic cancers","","Hepatobiliary and pancreatic (HBP) cancers are among the most aggressive malignancies, with recurrence and metastasis driven by tumor heterogeneity and drug resistance, making effective treatment difficult. Personalized and accurate prediction models are still lacking. Patient-derived organoids (PDOs) are three-dimensional in vitro models built from individual patient tumor tissues, with cultivation success rates consistently exceeding 70% and predictive accuracy surpassing 90%. Key limitations include inadequate simulation of the tumor microenvironment and insufficient assessment of multi-drug combination efficacy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/applications-and-challenges-of-patient-derived-organoids-in-hepatobiliary-and-pancreatic-cancers/365801/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/applications-and-challenges-of-patient-derived-organoids-in-hepatobiliary-and-pancreatic-cancers/365801.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are hepatobiliary and pancreatic cancers challenging to treat?","Question",{"text":112,"@type":113},"They are highly aggressive, with recurrence and metastasis driven by tumor heterogeneity and drug resistance, and current personalized prediction models remain limited.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are patient-derived organoids (PDOs) and what performance has been reported?",{"text":117,"@type":113},"PDOs are three-dimensional in vitro models created from individual patients’ tumor tissues. Reported cultivation success exceeds 70%, and predictive accuracy surpasses 90%.",{"name":119,"@type":110,"acceptedAnswer":120},"What major limitations still affect PDOs?",{"text":121,"@type":113},"PDOs have notable difficulty in accurately simulating the tumor microenvironment, including tumor angiogenesis and surrounding cellular context, even with co-culture and microfluidic approaches.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365801,1790379138,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","| W | J | G | World Journal of\u003Cbr>Gastroenterology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com)  \n[DOI:](DOI: 10.3748/wjg.v31.i20.106747)[ 10.3748/wjg.v31.i20.106747](DOI: 10.3748/wjg.v31.i20.106747)  \nWorld J Gastroenterol 2025 May 28; 31(20): 106747 ISSN 1007-9327 (print) ISSN 2219-2840 (online)  \nMINIREVIEWS  \nApplications and challenges of patient-derived organoids in hepatobiliary and pancreatic cancers  \nJia-Wei Hu, Yan-Zhi Pan, Xiao-Xiao Zhang, Jiang-Tao Li, Yun Jin  \nSpecialty type: Gastroenterology and hepatology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade A, Grade B, Grade C  \nNovelty: Grade B, Grade B, Grade C  \nCreativity or Innovation: Grade A, Grade B, Grade C  \nScientific Significance: Grade A, Grade B, Grade C  \nP-Reviewer: Alshammary RAA; Liu TF; Lv CM  \nReceived: March 6, 2025  \nRevised: April 12, 2025  \nAccepted: May 12, 2025  \nPublished online: May 28, 2025  \nProcessing time: 83 Days and 2.8 Hours  \nJia-Wei Hu, Yan-Zhi Pan, Xiao-Xiao Zhang, Jiang-Tao Li, Yun Jin, Department of Hepatic-BiliaryPancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, China  \nCo-first authors: Jia-Wei Hu and Yan-Zhi Pan.  \nCo-corresponding authors: Yun Jin and Jiang-Tao Li.  \nCorresponding author: Yun Jin, MD, Associate Chief Physician, Department of HepaticBiliary-Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China.  \n[jinyunzeyy@zju.edu.cn](jinyunzeyy@zju.edu.cn)  \nAbstract  \nHepatobiliary and pancreatic (HBP) cancers are among the most aggressive malignancies, with recurrence and metastasis driven by tumor heterogeneity and drug resistance, presenting considerable challenges to effective treatment. Currently, personalized and accurate treatment prediction models for these cancers are lacking. Patient-derived organoids (PDOs) tumor are three-dimensional in vitro models created from the tumor tissues of individual patients. Recent reports and our cultivation data indicate that the success rate of cultivating organoids for HBP cancers consistently exceeds 70% . The predictive accuracy of these tumor organoids has been shown to surpass 90% . However, PDOs still face notable limitations, especially in simulating the tumor microenvironment, including tumor angiogenesis and the surrounding cellular context, which require further refinement. While co-culture techniques and microfluidic platforms have been developed to mimic multi-cellular environments and functional vascular perfusion, they remain insufficient in accurately recapitulating the complexities of the in vivo environment. Additionally, PDOs are needed to fully assess their potential in predicting the efficacy of multi-drug combination therapies. This review providesan overview of the applications, challenges, and prospects for organoid models in the study of HBP cancer.  \nKey Words: Patient-derived tumor organoids; Hepatobiliary and pancreatic cancers; Tumor microenvironment; Co-culture; Drug prediction  \n©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.  \n WJG  [https://www.wjgnet.com](https://www.wjgnet.com) 1 May 28, 2025  Volume 31  Issue 20   \nHu JW et al. PDOs in hepatobiliary and pancreatic cancers  \nCore Tip: Hepatobiliary and pancreatic (HBP) cancers are highly aggressive, with recurrence and metastasis driven by tumor heterogeneity and drug resistance, posing significant treatment challenges. Current personalized and accurate prediction models are lacking. Patient-derived organoids (PDOs) tumor, three-dimensional in vitro models from patient tumor tissues, show over 70% cultivation success and over 90% predictive accuracy. However, PDOs face limitations in simula","cbCaisn7jq1TVhD4","https://ap.wps.com/l/cbCaisn7jq1TVhD4","pdf",1632233,13,"English","# MINIREVIEWS\n## Core Tip\n## Abstract\n## Key Words","[{\"question\":\"Why are hepatobiliary and pancreatic cancers challenging to treat?\",\"answer\":\"They are highly aggressive, with recurrence and metastasis driven by tumor heterogeneity and drug resistance, and current personalized prediction models remain limited.\"},{\"question\":\"What are patient-derived organoids (PDOs) and what performance has been reported?\",\"answer\":\"PDOs are three-dimensional in vitro models created from individual patients’ tumor tissues. Reported cultivation success exceeds 70%, and predictive accuracy surpasses 90%.\"},{\"question\":\"What major limitations still affect PDOs?\",\"answer\":\"PDOs have notable difficulty in accurately simulating the tumor microenvironment, including tumor angiogenesis and surrounding cellular context, even with co-culture and microfluidic approaches.\"}]","Applications and challenges of patient-derived organoids in hepatobiliary and pancreatic cancers | PDF",1790162382,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a911a5936510026f0641505035b30f88.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b81316c9188d63f3cdf39b586793247.webp",982,1389,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58d346289699c35538ca86472558e54d.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67cc6c760ef5b5de3935cfdc2c5e9322.webp",980,1386]